UCB SA (UCB) announced that it has received a complete response letter from the U.S. Food and Drug Administration or FDA, recommending reformulation of Neupro before making it available in the U.S. market for the treatment of Parkinson's disease and restless legs syndrome.
FDA's response is to an NDA Supplement that UCB submitted in June 2009, with a proposal for new refrigerated storage conditions to alleviate crystallization on the patches.
More than 50 thousand patients are being treated by Neupro in Europe. In the U.S., a Patient Access Program is ongoing and UCB will continue this program.
About Neupro in Europe Neupro is approved in the European Union for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as monotherapy or in combination with levodopa.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.